Editorial

. 2022 Aug 10;60(2):2200803.

doi: 10.1183/13993003.00803-2022. Print 2022 Aug.

Update June 2022: management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline

Nicolas Roche^{1

2}, Megan L Crichton³, Pieter C Goeminne⁴, Bin Cao⁵, Marc Humbert⁶, Michal Shteinberg⁷, Katerina M Antoniou⁸, Charlotte Suppli Ulrik⁹, Helen Parks¹⁰, Chen Wang¹¹, Thomas Vandendriessche¹², Jieming Qu^{13

14}, Daiana Stolz¹⁵, Christopher Brightling¹⁶, Tobias Welte¹⁷, Stefano Aliberti¹⁸, Anita K Simonds¹⁹, Thomy Tonia²⁰, James D Chalmers^{21

2}

Affiliations

¹ Respiratory Medicine, Cochin Hospital, APHP Centre-University of Paris, Cochin Institute (INSERM UMR1016), Paris, France.
² N. Roche and J.D. Chalmers are task force co-chairs.
³ School of Medicine, University of Dundee, Dundee, UK.
⁴ Department of Respiratory Medicine, AZ Nikolaas, Sint-Niklaas, Belgium.
⁵ Department of Respiratory and Critical Care Medicine, Clinical Microbiology and Infectious Disease Lab, China-Japan Friendship Hospital, National Center for Respiratory Medicine, Institute of Respiratory Medicine, Chinese Academy of Medical Science, National Clinical Research Center of Respiratory Diseases, Beijing, China.
⁶ Service de Pneumologie et Soins Intensifs, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Saclay, Inserm UMR_S 999, Le Kremlin Bicêtre, France.
⁷ Pulmonology institute and CF Center, Carmel Medical Center and the Technion-Israel Institute of Technology, Haifa, Israel.
⁸ Laboratory of Molecular and Cellular Pneumonology, Department of Respiratory Medicine, School of Medicine, University of Crete, Heraklion, Greece.
⁹ Department of Respiratory Medicine, Copenhagen University Hospital-Hvidovre Hospital, Hvidovre, Denmark.
¹⁰ European Lung Foundation, Sheffield, UK.
¹¹ Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center of Respiratory Diseases, Beijing, China.
¹² KU Leuven Libraries - 2Bergen - Learning Centre Désiré Collen, Leuven, Belgium.
¹³ Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, Shanghai, China.
¹⁴ Institute of Respiratory Diseases, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
¹⁵ Clinic of Respiratory Medicine and Pulmonary Cell Research, University Hospital Basel, Basel, Switzerland.
¹⁶ Institute for Lung Health, Leicester NIHR BRC, University of Leicester, Leicester, UK.
¹⁷ Medizinische Hochschule Hannover, Hannover, Germany.
¹⁸ University of Milan, Department of Pathophysiology and Transplantation, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
¹⁹ Respiratory and Sleep Medicine, Royal Brompton and Harefield NHS Foundation Trust, London, UK.
²⁰ Institute of Social and Preventive Medicine, University Bern, Bern, Switzerland.
²¹ School of Medicine, University of Dundee, Dundee, UK jchalmers@dundee.ac.uk.

PMID: 35710264
PMCID: PMC9363848
DOI: 10.1183/13993003.00803-2022

Editorial

Update June 2022: management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline

Nicolas Roche et al. Eur Respir J. 2022.

. 2022 Aug 10;60(2):2200803.

doi: 10.1183/13993003.00803-2022. Print 2022 Aug.

Authors

Affiliations

¹ Respiratory Medicine, Cochin Hospital, APHP Centre-University of Paris, Cochin Institute (INSERM UMR1016), Paris, France.
² N. Roche and J.D. Chalmers are task force co-chairs.
³ School of Medicine, University of Dundee, Dundee, UK.
⁴ Department of Respiratory Medicine, AZ Nikolaas, Sint-Niklaas, Belgium.
⁵ Department of Respiratory and Critical Care Medicine, Clinical Microbiology and Infectious Disease Lab, China-Japan Friendship Hospital, National Center for Respiratory Medicine, Institute of Respiratory Medicine, Chinese Academy of Medical Science, National Clinical Research Center of Respiratory Diseases, Beijing, China.
⁶ Service de Pneumologie et Soins Intensifs, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Saclay, Inserm UMR_S 999, Le Kremlin Bicêtre, France.
⁷ Pulmonology institute and CF Center, Carmel Medical Center and the Technion-Israel Institute of Technology, Haifa, Israel.
⁸ Laboratory of Molecular and Cellular Pneumonology, Department of Respiratory Medicine, School of Medicine, University of Crete, Heraklion, Greece.
⁹ Department of Respiratory Medicine, Copenhagen University Hospital-Hvidovre Hospital, Hvidovre, Denmark.
¹⁰ European Lung Foundation, Sheffield, UK.
¹¹ Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center of Respiratory Diseases, Beijing, China.
¹² KU Leuven Libraries - 2Bergen - Learning Centre Désiré Collen, Leuven, Belgium.
¹³ Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, Shanghai, China.
¹⁴ Institute of Respiratory Diseases, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
¹⁵ Clinic of Respiratory Medicine and Pulmonary Cell Research, University Hospital Basel, Basel, Switzerland.
¹⁶ Institute for Lung Health, Leicester NIHR BRC, University of Leicester, Leicester, UK.
¹⁷ Medizinische Hochschule Hannover, Hannover, Germany.
¹⁸ University of Milan, Department of Pathophysiology and Transplantation, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
¹⁹ Respiratory and Sleep Medicine, Royal Brompton and Harefield NHS Foundation Trust, London, UK.
²⁰ Institute of Social and Preventive Medicine, University Bern, Bern, Switzerland.
²¹ School of Medicine, University of Dundee, Dundee, UK jchalmers@dundee.ac.uk.

PMID: 35710264
PMCID: PMC9363848
DOI: 10.1183/13993003.00803-2022

Abstract

The ERS COVID-19 guidelines make recommendations for corticosteroids, anti-IL-6 monoclonal antibodies, baricitinib, anticoagulation and non-invasive respiratory support for hospitalised patients with COVID-19 https://bit.ly/3QgHH7U

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: N. Roche reports grants and personal fees from Boehringer Ingelheim, Novartis and Pfizer, personal fees from GSK, AstraZeneca, Chiesi, Sanofi and Zambon, outside the submitted work. M.L. Crichton reports personal fees from AstraZeneca, outside the submitted work. P.C. Goeminne reports personal fees for lectures from GSK and AstraZeneca, grants, personal fees for advisory board work and non-financial support for meeting attendance from Chiesi, outside the submitted work. B. Cao reports personal fees from F. Hoffmann-La Roche Ltd as a member of steering committee in transmission study of baloxavir, and grants from Peking Union Medical College Foundation, outside the submitted work. M. Humbert reports grants, personal fees and non-financial support from GlaxoSmithKline, personal fees from AstraZeneca, Novartis, Roche, Sanofi, Teva and Merck, grants and personal fees from Acceleron, Actelion and Bayer, outside the submitted work. M. Shteinberg reports grants, personal fees and non-financial support from GSK, grants and personal fees from Novartis, personal fees from Boehringer Ingelheim, AstraZeneca, Kamada, Vertex pharmaceuticals, Teva and Zambon, non-financial support from Actelion and Rafa, outside the submitted work. C.S. Ulrik reports personal fees from AstraZeneca, GSK, Chiesi, Orion Pharma and TEVA, grants and personal fees from Boehringer Ingelheim, Sanofi Genzyme and Novartis, grants from Mundipharma, outside the submitted work. D. Stolz reports grants from AstraZeneca AG, Curetis AG and Boston Scientific, lecture fees from AstraZeneca AG, Novartis AG, GSK AG, Roche AG, Zambon, Pfizer, Schwabe Pharma AG and Vifor AG, outside the submitted work. T. Welte reports grants from German Ministry of Health, German Ministry of Research and Education, DFG, WHO and EU, during the conduct of the study; personal fees for lectures/advisory board work from Roche, AstraZeneca, Boehringer, GSK and Novartis, outside the submitted work. S. Aliberti reports personal fees for advisory board work and research support from Bayer Healthcare, personal fees for lectures from Grifols and Menarini, personal fees for advisory board work from AstraZeneca and ZetaCube Srl, personal fees for advisory board work and lectures from Zambon and GlaxoSmithKline, grants and personal fees advisory board work and lectures from Chiesi and INSMED, grants from Fisher & Paykel, outside the submitted work. T. Tonia acts as ERS Methodologist. J.D. Chalmers reports grants and personal fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and Insmed, personal fees from Chiesi, Novartis and Zambon, grants from Gilead Sciences, outside the submitted work. The remaining authors disclose no potential conflicts of interest.

Figures

**FIGURE 1**
Summary of the European Respiratory Society guideline for management of hospitalised patients with COVID-19. ^#: high flow nasal oxygen (HFNO) is recommended where continuous positive airway pressure (CPAP) is contraindicated or not tolerated. ^¶: in addition, this therapy is only recommended where a susceptible variant is dominant, or rapid testing is available to confirm a susceptible variant. IL: interleukin.

See this image and copyright information in PMC

Comment on

Biomarkers to identify Mycobacterium tuberculosis infection among borderline QuantiFERON results.
Uzorka JW, Bakker JA, van Meijgaarden KE, Leyten EMS, Delfos NM, Hetem DJ, Kerremans J, Zwarts M, Cozijn S, Ottenhoff THM, Joosten SA, Arend SM. Uzorka JW, et al. Eur Respir J. 2022 Aug 10;60(2):2102665. doi: 10.1183/13993003.02665-2021. Print 2022 Aug. Eur Respir J. 2022. PMID: 35058249 Free PMC article.

References

1. Huang C, Wang Y, Li X, et al. . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497–506. doi:10.1016/S0140-6736(20)30183-5 - DOI - PMC - PubMed
1. Zhu N, Zhang D, Wang W, et al. . A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382: 727–733. doi:10.1056/NEJMoa2001017 - DOI - PMC - PubMed
1. da Costa VG, Moreli ML, Saivish MV. The emergence of SARS, MERS and novel SARS-2 coronaviruses in the 21st century. Arch Virol 2020; 165: 1517–1526. doi:10.1007/s00705-020-04628-0 - DOI - PMC - PubMed
1. Xu J, Cao B. Lessons learnt from hydroxychloroquine/azithromycin in treatment of COVID-19. Eur Respir J 2022; 59: 2102002. - PMC - PubMed
1. Yan D, Liu X-Y, Zhu Y-N, et al. . Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection. Eur Respir J 2020; 56: 2000799. doi:10.1183/13993003.00799-2020 - DOI - PMC - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Update June 2022: management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline

Affiliations

Update June 2022: management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

Comment on

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Research Materials

Miscellaneous